Agriforce (AGRI) Director Reports Share Purchases and Option Holdings
Rhea-AI Filing Summary
David Ryan Welch, a director of Agriforce Growing Systems Ltd. (AGRI), reported multiple equity transactions and option holdings. The Form 4 shows acquisitions of 84,388 common shares on 09/18/2025 at a per-share price of $2.37, and 13,022 common shares on 05/21/2025 at $11.79. An earlier transaction on 05/17/2024 shows 11 shares at $129.42. Following these transactions the reporting person beneficially owns 97,421 common shares. Several stock options are reported (small quantities of underlying shares after adjustments) with various exercise prices and vesting schedules. A January 16, 2025 lockup restricts sales for one year. Multiple reverse splits (2023, 2024, 2025) were applied to reported amounts and prices.
Positive
- Director increased direct ownership through purchases totaling 97,410 shares added in 2025 (84,388 and 13,022), bringing total beneficial ownership to 97,421.
- Stock options in place with multi-year vesting align management incentives with company performance over time.
- One-year lockup from January 16, 2025 restricts sales by the reporting person, indicating a period of alignment with shareholders.
Negative
- Potential dilution from outstanding stock options, although reported post-adjustment option share counts are small.
- Multiple reverse stock splits (2023, 2024, 2025) complicate historical comparisons of grant sizes and prices.
Insights
TL;DR: Director acquisitions increase reported beneficial ownership to 97,421 shares; multiple option grants and lockup noted.
The reported purchases on 05/21/2025 and 09/18/2025 materially increased the director's direct holdings to 97,421 shares. The filing also documents previously granted stock options (with modest remaining share counts after adjustment) and standard multi-year vesting schedules. The January 2025 lockup limits immediate disposition of shares for one year, reducing short-term selling pressure from this insider. Multiple reverse splits have adjusted historical grant sizes and prices, which complicates direct period-to-period comparisons but do not alter the substance of current ownership.
TL;DR: Transaction disclosure is complete and shows standard director compensation, vesting, and a time-limited lockup agreement.
The Form 4 provides clear disclosure of direct purchases, option awards, vesting terms, and a lockup executed in January 2025. Vesting schedules that require continued service align with typical governance practices. The lockup and the director status are notable governance facts for stakeholders assessing insider alignment and potential selling constraints. The filing does not disclose any departures, related-party conflicts, or unusual acceleration provisions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Shares | 84,388 | $2.37 | $200K |
| Grant/Award | Common Shares | 13,022 | $11.79 | $154K |
| Purchase | Common Shares | 11 | $129.42 | $1K |
| Grant/Award | Stock Options | 3 | $0.00 | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
Footnotes (1)
- Represents Common Shares granted to the Reporting Person that are restricted and subject to a lockup agreement entered into by the Reporting Person in January 2025. Pursuant to the lockup agreement, the Director may not sell any Common Shares owned by the Reporting Person for one year from January 16, 2025 (subject to the ability to sell shares received by each as the result of an employment agreement at any time). Equals the per share closing price on September 17, 2025. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. As adjusted for a reverse split that occurred on July 30, 2025. The original grant was 117,206 Common Shares. As adjusted for a reverse split that occurred on July 30, 2025. The original price per share was $1.31. As adjusted for a reverse split that occurred on (i) December 6, 2024 and (ii) July 30, 2025. The original grant was 9,900 Common Shares. As adjusted for a reverse split that occurred on (i) December 6, 2024 and (ii) July 30, 2025. The original price per share was $0.1515. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original exercise price was $0.09. If permitted by the policies of any stock exchange on which the Issuer may be listed from time to time, the stock option may be exercised by means of a "cashless exercise", in which event the Issuer shall issue to the holder the net number of common shares determined based on the formula presented in the exhibit to the stock option certificate. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original grant was 156,876 Stock Options. The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche to be vested on the three-month anniversary of date of grant of September 12, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original exercise price was $1.14. The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche to be vested on the three-month anniversary of date of grant of November 18, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original grant was 24,447 Stock Options. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original exercise price was $7.00. The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche to be vested on the three-month anniversary of date of grant of May 31, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. As adjusted for the following: (i) a 1 for 50 reverse split that occurred on October 12, 2023, (ii) a 1 for 100 reverse split that occurred on December 6, 2024, and (iii) a 1 for 9 reverse split that occurred on July 30, 2025. The original grant was 24,642 Stock Options.